The effect of meloxicam, a selective COX-2 inhibitor, on the microvasculature of small metastatic liver tumors in rats

Japanese Journal of Clinical Oncology

Volumn 37, Issue 9, 2007, Pages 673-678

  Iwase, Naoko ^a   Higuchi, Tetsuro ^a   Gonda, Tsuyoshi ^b   Kobayashi, Hirotoshi ^a   Uetake, Hiroyuki ^a   Enomoto, Masayuki ^a   Sugihara, Kenichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Colorectal carcinoma; COX 2; Liver metastasis; Microvasculature

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COLON CANCER; CONTROLLED STUDY; DRUG DOSE COMPARISON; LIVER METASTASIS; MALE; METASTASIS INHIBITION; MICROVASCULATURE; NONHUMAN; RAT; SCANNING ELECTRON MICROSCOPY; STEREOMICROSCOPY; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; LIVER NEOPLASMS; MALE; MICROCIRCULATION; MICROSCOPY, ELECTRON, SCANNING; RATS; RATS, INBRED F344; THIAZINES; THIAZOLES;

EID: 35448956937     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym081     Document Type: Article

References (51)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer Statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Muto T, Kotake K, Koyama Y. Colorectal cancer statistics in Japan: Data from JSCCR registration, 1974-1993. Int J Clin Oncol 2001;6:171-6.
3. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988;48:4399-404.
4. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. New Engl J Med 1991;325:1593-6.
5. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willet WC, et al. Aspirin and the risk of colorectal cancer in women. New Engl J Med 1995;333:609-14.
6. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993;72:1171-7.
7. Peleg II, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994;154:394-9.
8. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983;24:83-7.
9. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. New Engl J Med 1993;328:1313-6.
10. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New Engl J Med 2000;342:1946-52.
11. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: Structural, cellular, and molecular biology. A Rev Biochem 2000;69:145-82.
12. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastrointerology 1994;107:1183-8.
13. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-9.
14. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-16.
15. Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998;58:4823-6.
16. Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996;93:4816-20.
17. Smalley WE, DuBois RN. Colorectal cancer and non steroidal anti-inflammatory drugs. Adv Pharmac 1997;39:1-20.
18. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
19. Nagatsuka I, Yamada N, Shimizu S, Ohira M, Nishino H, Seki S, et al. Inhibitory effect of a selective COX-2 inhibitor on liver metastasis of colon cancer. Int J Cancer 1997;76:582-587.
20. Matsunaga N, Yamada N, Ohira M, Tachimori A, Nishiguchi Y, Nishino H, et al. Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer. Oncol Rep 2004;11:167-71.
21. Gutman M, Fidler IJ. Biology of human colon cancer metastasis. World J Surg 1995;19:226-34.
22. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer 1996;32A:2451-60.
23. Folkman J. Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastasis Rev 1990;9:171-4.
24. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974;34:997-1004.
25. Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1990;1032:89-118.
26. Nagy JA, Brown LF, Senger DR, Lanir N, Van de Water L, Dvorak AM, et al. Pathogenesis of tumor stroma generation: A critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1989;948:305-26.
27. Gonda T, Ishida H, Yoshinaga K, Sugihara K. Microvasculature of small liver metastases in rats. J Surg Res 2000;94:43-8.
28. Kobayashi H, Gonda T, Uetake H, Higuchi T, Enomoto M, Sugihara K. JTE-522, a selective COX-2 inhibitor, interferes with the growth of lung metastases from colorectal cancer in rats due to inhibition of neovascularization: A vascular cast model study. Int J Cancer 2004;112:920-6.
29. Pairet M, Van Ryn J, Schierok H, Mauz A, Trummlitz G, Engelhardt G. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4′-isomer. Inflamm Res 1998;47:270-6.
30. Okuno K, Hirai N, Lee YS, Kawai I, Shigeoka H, Yasutomi M. Involvement of liver-associated immunity in hepatic metastasis formation. J Surg Res 1998;75:148-52.
31. Inoue Y, Kashima Y, Aizawa K, Hatakeyama K. A new rat colon cancer cell line metastasizes spontaneously: Biologic characteristics and chemotherapeutic response. Jpn J Cancer Res 1991;82:90-7.
32. Murakami T. Application of the scanning electron microscope to the study of the fine distribution of blood vessels. Arch Histol Jpn 1971;32:445-54.
33. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
34. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part 1). J Natl Cancer Inst 1998;90:1529-36.
35. Sheehan KM, Sheahan K, O'Donoghne DP, MacSweeney F, Conroy RM, Fitzgerald DJ, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999;282:1254-7.
36. Hasegawa K, Ichikawa W, Fujita T, Ohno R, Okusa T, Yoshinaga K, et al. Expression of cyclooxygenase-2 (COX-2) mRNA in human colorectal adenomas. Eur J Cancer 2001;37:1469-74.
37. Sato T, Yoshinaga K, Okabe S, Okawa T, Enomoto M, Takizawa T, et al. Cyclooxygenase-2 expression in colorectal adenomas. Dis Colon Rectum 2003;46:786-92.
38. Reddy BS, Rao C, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996;56:4566-9.
39. Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, et al. Chemoprevention of intestinal polyposis in the Apedelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001;61:1733-40.
40. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58;409-12.
41. Yao M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003;63:586-92.
42. Goldman AP, Willams CS, Sheng H, Lamps LW, Williams VP, Pairet M, et al. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 1998;19:2195-9.
43. Hussey HJ, Tisdale MJ. Effect of polyunsaturated fatty acids on the growth of murine colon adenocarcinomas in vitro and in vivo. Br J Cancer 1994;70:6-10.
44. Ishida H, Iwama T, Mishima Y. The significance of portal vein chemotherapy for liver micrometastases: An experimental study of a rat model. Surg Today 1994;24:900-5.
45. Hussey HJ, Tisdale MJ. Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model. Int J Cancer 2000;87:95-100.
46. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 2002;62:6323-8.
47. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-6.
48. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Selective cyclooxygenase-2 inhibitiors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 2002;531:278-84.
49. Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A, et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001;121:1339-47.
50. Yoshida S, Amano H, Hayashi I, Kitasato H, Kamata M, Inukai M, et al. COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Lab Invest 2003;83:1385-94.
51. Fenwick SW, Toogood GJ, Lodge JP, Hull MA. The effect of the selective cylooxygenase-2 inhibitor rofecoixb on human colorectal cancer liver metastases. Gastroenterology 2003;125:716-29.